• Executive interview - Race Oncology

    422 views 1 year ago
    Race Oncology is developing bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle’s search for a safer anthracycline chemotherapy. Despite positive responses in a variety of cancers, especially AML (it was even approved for the treatment of AML in France, but never commercialised), development stopped after Lederle was sold to Wyeth and then Wyeth to Pfizer. Race will be developing bisantrene initially for relapsed/refractory AML and expects to start a pivotal trial for approval in the US around the end of 2018. Show less
    Read more
  • Uploads Play all

    • Bitesize briefing - Hard rock lithium strip ratios. Why you should care? - Duration: 94 seconds.

      • 6 hours ago
      • No views
      In this video we look at the strip ratios of hard rock lithium projects. A strip ratio is the volume of waste or overburden that has to be removed for every tonne of ore extracted. Removing and han...
    • Executive interview – Hermes Investment Management - Duration: 3 minutes, 54 seconds.

      • 4 days ago
      Andrew Parry, Head of Sustainable Investing at Hermes Investment Management, talks to us about the company’s commitment to delivering holistic returns – outcomes which consider the impact that deci...
    • Bitesize briefing – Allied Minds - Duration: 9 minutes, 55 seconds.

      • 4 days ago
      Allied Minds is an IP commercialisation company focusing on early-stage companies within life sciences and technology. Although AIM listed, its portfolio companies are spin-outs from US federal gov...
    • The hard rock lithium grade curve – what is high grade? - Duration: 2 minutes, 46 seconds.

      • 6 days ago
      In this video we look at the grade curve of hard rock lithium projects. We believe this video gives the viewer the context required to validate what a company is saying about the grade of its deposit.
    • Hard rock lithium grade/tonnage distribution - how does your investment compare? - Duration: 4 minutes, 25 seconds.

      • 1 week ago
      In this video we look at the grade/tonnage distribution of hard rock lithium projects so that individual assets can be compared with the wider peer group, giving interested investors some much need...
    • Mobile World Congress – key themes - Duration: 8 minutes, 24 seconds.

      • 1 week ago
      Dan Ridsdale, Edison’s global head of TMT discusses some of the key themes from the MWC 2019. 5G, Foldable screens, Internet of things, VR/AR and the growth in the second hand handset market.
    • Executive interview – ROVI - Duration: 4 minutes, 13 seconds.

      • 1 week ago
      Laboratorios Farmacéuticos ROVI is a fully integrated, profitable Spanish pharmaceutical company established in 1946 that listed on the Madrid Stock Exchange in 2007. ROVI is involved in the resear...
    • XP Power FY18 results - Duration: 7 minutes, 47 seconds.

      • 1 week ago
      In this interview, CEO Duncan Penny and CFO Gavin Griggs discuss XP Power’s FY18 results. Gavin explains the company’s record performance in terms of revenues, profits and bookings despite currency...
    • Executive interview - Algebris - Duration: 4 minutes, 51 seconds.

      • 1 week ago
      Algebris, with €11bn AUM, is a global investment manager that embraces long-only and alternative strategies. Founded in 2006 by CEO David Serra, Algebris has broadened its financials sector experti...
    • Fund manager interview – Polar Capital - Duration: 5 minutes, 38 seconds.

      • 2 weeks ago
      Nick Brind, co-manager of the Polar Capital Global Financials Trust (PCFT), discusses why the world’s largest sector (by market cap) could generate substantially different returns over the next dec...
    • Bitesize briefing - UK video games - Duration: 6 minutes, 38 seconds.

      • 2 weeks ago
      Over the past two to three years, we have seen the re-emergence of a listed small- and mid-cap games sector in the UK and Europe, with a wave of IPOs supported by a period of sustained outperforman...
    • Executive interview - Cantargia - Duration: 4 minutes, 29 seconds.

      • 2 weeks ago
      Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing antibodies against target IL1RAP to treat c...
    This item has been hidden
  • This item has been hidden
to add this to Watch Later

Add to

Loading playlists...